Federal regulators have approved an alternative version of Remicade, an expensive injected drug widely used for rheumatoid arthritis and other immune system disorders.
The Food and Drug Administration said Friday that it approved Renflexis, developed by Samsung Bioepis Co. of South Korea. It will be marketed by its U.S. partner, Merck & Co. of Kenilworth, New Jersey.
The companies refused to disclose the list price. Without insurance, Remicade generally costs more than $30,000 annually for adults; dosage varies with the patient’s weight.
Merck said Renflexis should be available in six months. The delay is required under U.S. regulations for a relatively new category called biosimilars. That’s the industry term for generic but not quite identical versions of biotech drugs.
Most Read Stories
- Road rage in Kent: Subaru strikes Jeep three times
- Did you get the letter? WSU sends warning to 1 million people after hard drive with personal info is stolen
- UW professor got it right on Trump. So why is he being ignored? | Danny Westneat
- Veteran LAPD officer arrested for sex with 15-year-old cadet
- The Amazon effect: Metro adds buses to handle new flock of summer interns